CHNA

Fund Description
The Loncar China BioPharma ETF trades on Nasdaq under the symbol CHNA. It is made of up a basket of companies that are leading China s biotech revolution. With a focus on innovators, the fund contains globally listed pharmaceutical companies, biotech companies, drug manufacturers, diagnostics companies, wholesalers, distributors and service providers that have a strategic role in growing China s drug industry. CHNA ETF offers this global exposure all in the convenience of one security that trades in the United States. It tracks the LCHINA index.
Fund Profile
Fund Name Loncar China Biopharma ETF
Fund Exchange Ticker CHNA
Fund Sponsor Exchange Traded Concepts
Fund ISIN US26922A3703
Net Expense Ratio 0.79 %
Fund Inception Date 14 August 2018
Fund Legal Structure ETF (Open end fund)
Exchange NASDAQ
Listing Country Code US
Fund Investment Objective
ETF Type Specific Global or ExUS Equities - Industry Sector
Asset Class Equities (Stocks)
Index Linked Passive
Index Name Loncar China BioPharma Index
Index Provider Loncar Investments
Currency Hedged No
Inverse / Leveraged Not Applicable
Developed / Emerging Emerging Market Funds
Market Capitalization Range Broad Market / Multi-Cap
Growth Value Core / Blend
Continent Asia
Key Statistics
Return As of Date 21 January 2021
Asset Under Management 14.48 Million (USD)
1 Month Total Return 22.02 %
Year To Date Return 18.10 %
1 Year Total Return 46.68 %
3 Year Annualized Total Return
NAV 38.6035
Share Outstanding 375,000
Top 10 Holdings (20 January 2021)
Constituent Name Constituent Ticker Constituent Type Weighting
WUXI BIOLOGICS CAYMAN INC 2269 EQUI 0.0479000000
PHARMARON BEIJING CO LTD-H 3759 EQUI 0.0434000000
ZAI LAB LTD-ADR ZLAB EQUI 0.0384000000
BEIGENE LTD-ADR BGNE EQUI 0.0377000000
WUXI APPTEC CO LTD-H 2359 EQUI 0.0354000000
SHANGHAI JUNSHI BIOSCIENCE-H 1877 EQUI 0.0349000000
INNOVENT BIOLOGICS INC 1801 EQUI 0.0330000000
HANSOH PHARMACEUTICAL GROUP 3692 EQUI 0.0329000000
SIHUAN PHARMACEUTICAL HLDGS 460 EQUI 0.0323000000
I MAB IMAB EQUI 0.0320000000